Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 4, 2026 · Other material event · Financial statements
Kairos Pharma, LTD.
8
Other material event
Jun 4, 2026
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Kairos Pharma, LTD. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders LOS ANGELES, June 4, 2026 – (Business Wire) – Kairos Pharma Ltd . (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Kairos Pharma, LTD. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
